Monitoring Patients After a Change in Treatment Regimen
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, review conditions under which they would assess treatment success for patients who have changed therapies.
EP: 1.The Value of Biomarker in Multiple Sclerosis
EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis
EP: 3.Assays to Detect Neurofilament Light
EP: 4.Challenges and Opportunity With MRI
EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions
EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care
EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI
EP: 8.How to Address Increasing Neurofilament Light Chain Levels
EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels
EP: 10.Monitoring Patients After a Change in Treatment Regimen
EP: 11.Assessing Lesion Types With MS Biomarkers
EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease
EP: 13.The CLIMB Study
EP: 14.Reimbursement for MRI
EP: 15.Understanding the Underlying Progression of Multiple Sclerosis
EP: 16.Biomarkers, Patient Communication, and the Future of Care
EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers
In this segment, the discussion shifts towards the utility of monitoring NFL in comparison to MRI for patients on MS therapy. Experts inquire about the possibility of using NFL to reduce the frequency of MRI scans, particularly in regions with limited access to MRI machines.
They acknowledge the potential cost-saving benefit of using NFL to confidently space out MRI scans. Experts introduce the concept of confirmed NFL elevation to ensure the accuracy of NFL changes and discusses the intriguing aspect of non-correlation between contrast-enhancing lesions and NFL levels.
Tanuja Chitnis, MD, emphasizes the importance of having an annual MRI for a comprehensive assessment of lesion location and status. However, she suggests using NFL every three months to monitor more frequently. The discussion touches on the challenge of interpreting lesions in older age and the need for further research to understand the correlation between NFL and contrast-enhancing lesions.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
